390 related articles for article (PubMed ID: 33015827)
1. Pathophysiology and treatment options for gastroesophageal reflux disease: looking beyond acid.
Sharma P; Yadlapati R
Ann N Y Acad Sci; 2021 Feb; 1486(1):3-14. PubMed ID: 33015827
[TBL] [Abstract][Full Text] [Related]
2. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
3. Utilization of wireless pH monitoring technologies: a summary of the proceedings from the esophageal diagnostic working group.
Richter JE; Pandolfino JE; Vela MF; Kahrilas PJ; Lacy BE; Ganz R; Dengler W; Oelschlager BK; Peters J; DeVault KR; Fass R; Gyawali CP; Conklin J; DeMeester T;
Dis Esophagus; 2013; 26(8):755-65. PubMed ID: 22882487
[TBL] [Abstract][Full Text] [Related]
4. Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors.
Gerson LB; Triadafilopoulos G; Sahbaie P; Young W; Sloan S; Robinson M; Miner PB; Gardner JD
BMC Gastroenterol; 2008 May; 8():15. PubMed ID: 18498663
[TBL] [Abstract][Full Text] [Related]
5. Dual Ambulatory pH Monitoring in Patients with Gastroesophageal Reflux Rendered Asymptomatic with Proton Pump Inhibitor Therapy.
Lin D; Triadafilopoulos G
Dig Dis Sci; 2015 May; 60(5):1343-9. PubMed ID: 25135815
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Gastroesophageal Reflux by Combined Multichannel Intraluminal Impedance and pH Monitoring and Esophageal Motility Patterns in Children with Esophageal Atresia.
Tong S; Mallitt KA; Krishnan U
Eur J Pediatr Surg; 2016 Aug; 26(4):322-31. PubMed ID: 26445355
[TBL] [Abstract][Full Text] [Related]
7. Refractory gastroesophageal reflux disease: advances and treatment.
Ates F; Francis DO; Vaezi MF
Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):657-67. PubMed ID: 24745809
[TBL] [Abstract][Full Text] [Related]
8. Most Patients With Gastroesophageal Reflux Disease Who Failed Proton Pump Inhibitor Therapy Also Have Functional Esophageal Disorders.
Abdallah J; George N; Yamasaki T; Ganocy S; Fass R
Clin Gastroenterol Hepatol; 2019 May; 17(6):1073-1080.e1. PubMed ID: 29913281
[TBL] [Abstract][Full Text] [Related]
9. How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related?
de Bortoli N; Nacci A; Savarino E; Martinucci I; Bellini M; Fattori B; Ceccarelli L; Costa F; Mumolo MG; Ricchiuti A; Savarino V; Berrettini S; Marchi S
World J Gastroenterol; 2012 Aug; 18(32):4363-70. PubMed ID: 22969200
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
[TBL] [Abstract][Full Text] [Related]
11. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
Azzam RS
Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
[TBL] [Abstract][Full Text] [Related]
12. Gastroesophageal reflux disease-related and functional heartburn: pathophysiology and treatment.
Miwa H; Kondo T; Oshima T
Curr Opin Gastroenterol; 2016 Jul; 32(4):344-52. PubMed ID: 27206157
[TBL] [Abstract][Full Text] [Related]
13. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
Schey R; Alla SP; Midani D; Parkman HP
Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
[TBL] [Abstract][Full Text] [Related]
14. Patients with refractory reflux symptoms often do not have GERD.
Herregods TV; Troelstra M; Weijenborg PW; Bredenoord AJ; Smout AJ
Neurogastroenterol Motil; 2015 Sep; 27(9):1267-73. PubMed ID: 26088946
[TBL] [Abstract][Full Text] [Related]
15. Gastroesophageal reflux disease in the obese: Pathophysiology and treatment.
Nadaleto BF; Herbella FA; Patti MG
Surgery; 2016 Feb; 159(2):475-86. PubMed ID: 26054318
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology and pharmacological treatment of gastroesophageal reflux disease.
Storr M; Meining A; Allescher HD
Dig Dis; 2000; 18(2):93-102. PubMed ID: 11060472
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiology of gastroesophageal reflux disease: new understanding in a new era.
Herregods TV; Bredenoord AJ; Smout AJ
Neurogastroenterol Motil; 2015 Sep; 27(9):1202-13. PubMed ID: 26053301
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
[TBL] [Abstract][Full Text] [Related]
19. Nocturnal gastric acid breakthrough is not associated with night-time gastroesophageal reflux in GERD patients.
Weigt J; Kandulski A; Büsch F; Malfertheiner P
Dig Dis; 2009; 27(1):68-73. PubMed ID: 19439964
[TBL] [Abstract][Full Text] [Related]
20. [The impact of proton pump inhibitors on esophageal acid exposure in gastroesophageal reflux disease].
Liang XY; Chen WN; Lan L; Wang Q; Lü YW; Lan Y
Zhonghua Nei Ke Za Zhi; 2012 Jul; 51(7):513-5. PubMed ID: 22943821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
